# US 2021/0230113 A1 · Cannabinoid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0230113 A1
- Document ID: US20210230113A1
- Status: Published application
- Kind: A1
- Application number: 17/155,569
- Filed: 2021-01-22
- Published: 2021-07-29
- Earliest claimed: 2020-01-24
- Assignees: PerkinElmer Health Sciences, Inc.
- Applicants: PerkinElmer Health Sciences, Inc.
- Inventors: Crist Filer
- Web page: https://patentgrep.com/patent/US20210230113A1

## CPC

- C07C 39/08: Dihydroxy benzenes; Alkylated derivatives thereof
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07B 59/001: {Acyclic or carbocyclic compounds}
- C07C 37/003: {by hydrogenation of an unsaturated part}
- C07C 37/14: by addition reactions, i.e. reactions involving at least one carbon-to-carbon unsaturated bond
- C07C 39/23: polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07C 2523/46: Ruthenium, rhodium, osmium or iridium
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This disclosure provides 8,9-dihydrocannabinoid derivatives, deuterated cannabinoid derivatives, and tritiated cannabinoid derivatives. The disclosure also provides compositions, methods of use, and processes of preparation of the foregoing derivatives.

## Claims

### Claim 1

A compound selected from the group consisting of
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

### Claim at position 10

11-120. (canceled)

### Claim 121

A compound of Formula (1)
or a pharmaceutically acceptable salt or solvate thereof,
wherein Y1 and Y2 are each independently hydrogen or deuterium,
is a single or a double bond,
and
Z is —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3 or

### Claim 122

(canceled)

### Claim 123 (depends on 121)

The compound of claim 121, wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 124 (depends on 123)

The compound of claim 123, wherein the compound is a compound of Formula A, or a pharmaceutically acceptable salt or solvate thereof.

### Claim 125

(canceled)

### Claim 126 (depends on 123)

The compound of claim 123, wherein the compound is a compound of Formula C, or a pharmaceutically acceptable salt or solvate thereof.

### Claim 127

(canceled)

### Claim 128 (depends on 121)

The compound of claim 121, wherein each of Y1 and Y2 is hydrogen.

### Claim 129

(canceled)

### Claim 130 (depends on 121)

The compound of claim 121, wherein is a single bond.

### Claim 131

(canceled)

### Claim 132 (depends on 121)

A pharmaceutical composition comprising a compound of claim 121, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable excipients.

### Claim 133

(canceled)

### Claim 134

A compound of Formula (2)
or a pharmaceutically acceptable salt or solvate thereof,
wherein Y1 and Y2 are each independently hydrogen or tritium,
is a single or a double bond,
provided that if is a double bond, then Z1 and Z2 are absent,
and provided that if is a single bond, then Z1 and Z2 are are each independently
hydrogen or tritium,
provided that the compound comprises tritium,
and
Z is —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3 or

### Claim 135

(canceled)

### Claim 136 (depends on 134)

The compound of claim 134, wherein the compound of Formula II is selected from the group consisting of
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 137 (depends on 136)

The compound of claim 136, wherein the compound is a compound of Formula E, or a pharmaceutically acceptable salt or solvate thereof.

### Claim 138

(canceled)

### Claim 139 (depends on 136)

The compound of claim 136, wherein the compound is a compound of Formula G, or a pharmaceutically acceptable salt or solvate thereof.

### Claim 140

(canceled)

### Claim 141 (depends on 134)

The compound of claim 134, wherein each of Y1 and Y2 is hydrogen.

### Claim 142

(canceled)

### Claim 143 (depends on 134)

The compound of claim 134, wherein is a single bond.

### Claim at position 34

144-152. (canceled)
